Introduction The optimal anticoagulation strategy for venous thromboembolism (VTE)
prevention among COVID-19 patients, hospitalized or in the community setting, is still …

Coagulopathy is an independent predictor of poor outcome in Coronavirus Disease of 2019
(COVID-19) patients [1]. Endothelial dysfunction, hypercoagulability, and platelet activation …

Objective Anticoagulation is crucial for patients hospitalized with coronavirus disease 2019
(COVID-19) due to the high risk of venous thromboembolism (VTE). However, the optimal …

The incidence of venous thromboembolism (VTE) events in patients with COVID-19 treated
with a standard thromboprophylaxis dose of anticoagulants remains high. We conducted a …

Abstract The coronavirus disease 2019 (COVID-19) pandemic is associated with high
virulence, mortality and healthcare burden around the world. One of its features is …

The aim of the study was to evaluate the efficacy and safety of increased doses of
anticoagulants in comparison with standard doses in inpatients with COVID-19. A systematic …

A high rate of thromboembolism and a high risk of death have been reported regarding
hospitalized patients with coronavirus disease 2019 (COVID-19). Recently, we noticed that …

Coronavirus disease 2019 (COVID-19) is a systemic disease that can be life-threatening
involving immune and inflammatory responses, and that can result in potentially lethal …

Anticoagulant therapy becomes critical to preventing further complications caused by the
hypercoagulative state in COVID-19 patients. The optimal dose and time-dependent …

We read with interest the study by Lynn et al. among 402 hospitalized COVID-19 patients,
which did not show any survival benefit in those who were administered therapeutic dosage …